Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

Healiva® Announces Strategic Collaboration With Lausanne University Hospital to Manufacture EpiDex® for Severe Chronic Wound Treatment

Healiva®, a patient-centric company delivering life-enhancing precision medicine for chronic wounds, announced today a strategic collaboration with Lausanne University Hospital (CHUV, ?Centre Hospitalier Universitaire Vaudois') for the manufacturing and approval of its autologous epidermal equivalent, Epidex®. Originating from the patient's own hair follicles, EpiDex® enables non-invasive treatment of severe chronic venous leg ulcers (VLUs).

"We are very pleased to partner with CHUV on EpiDex® production", said Dr. Priyanka Dutta-Passecker, Co-founder and CEO of Healiva. "Joining forces with a recognised centre of excellence in skin cell therapy marks a major milestone for the market launch plan for EpiDex®."

The partnership enables Healiva to access the GMP compliant manufacturing site of the CHUV Cell Production Centre (CHUV-CPC), its unique expertise in the development of Advanced Therapy Medicinal Products, and to combine the complementary competences of the partners for the treatment of chronic and acute wounds with cell therapy products.

To produce EpiDex®, cells originating from patient hair follicles will be cultured at the CHUV-CPC to generate small discs of autologous epidermis. Once delivered to the patient's treatment centre, these discs can be applied to the wound during a simple, non-surgical procedure, where they promote the growth and healing of the skin. The manufacturing of EpiDex® at CHUV-CPC will facilitate Healiva's plans to make EpiDex® available to patients in Switzerland.

"Healiva's technology represents a significant opportunity to change the way we treat people with chronic wounds," said Dr Jean-François Brunet (PhD), Director of CHUV-CPC. "We are fully committed to leveraging our experience in manufacturing technologies to support Healiva's manufacture of EpiDex®."

About EpiDex®

EpiDex® solves an urgent need for VLUs and other chronic wounds affecting 60 million patients worldwide. EpiDex® had been approved for the Swiss market until 2013 and will be relaunched initially in Switzerland, followed by EMEA countries.

About Healiva®

Founded in 2020 by Bioseutica and Dr. Dutta-Passecker, Healiva creates tailored solutions across the wound care spectrum through a multi-pronged approach combining enzyme technology, medical devices, and cell therapy.


CHUV-CPC produces cells and tissues to provide doctors and patients with cell and tissue therapy treatments. CHUV-CPC is a reference centre in the production of autologous skin for the treatment of burn patients.

These press releases may also interest you

at 01:51
Skanska has signed a contract with an existing client to build a data center in Arizona, USA. The contract is worth USD 82M, about SEK 870M, which will be included in the US order bookings for the fourth quarter of 2023. The project consists of a...

at 01:21
Hansa Biopharma, "Hansa" , today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in...

at 01:00
Global Identity Verification and Digital KYC solutions provider, Accura Scan is pleased to announce being awarded ISO/IEC 30107-03 compliance after passing a presentation attack detection (PAD) iBeta Level 2 audit with 0% FAR, making it one of the...

at 01:00
Trickster, the Austrian singer and entrepreneur from Linz, is releasing his amped up and swinging mash-up blend of Christmas classics 'Silent Night vs Santa Claus Is Coming To Town' on Trickster Recordings through Absolute and the story is building...

at 00:41
Sungrow, the global leading PV inverter and energy storage system supplier, announced its Volunteer Week for 2023 concluded a big success with thousands of volunteers joined in more than a dozen cities across the world....

at 00:30
Transformer Monitoring Market is expected to reach USD 3.7 billion by 2028 from USD 2.4 billion in 2023 at a CAGR of 9.1% during the 2023?2028 period according to a new report by MarketsandMarketstm. Transformer monitoring is critical for...

News published on and distributed by: